Morgan Stanley
MIRM icon

Morgan Stanley’s Mirum Pharmaceuticals MIRM Stock Holding History

Morgan Stanley’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1M Sell
351,404
-173,162
-33% -$17.4M ﹤0.01% 2428
2026
Q1 		$48.5M Buy
524,566
+98,881
+23% +$9.3M ﹤0.01% 2124
2025
Q4 		$33.6M Sell
425,685
-244,464
-36% -$17.5M ﹤0.01% 2473
2025
Q3 		$49.1M Buy
670,149
+103,823
+18% +$6.6M ﹤0.01% 2023
2025
Q2 		$28.8M Sell
566,326
-40,105
-7% -$1.79M ﹤0.01% 2449
2025
Q1 		$27.3M Sell
606,431
-151,949
-20% -$7.16M ﹤0.01% 2374
2024
Q4 		$31.4M Buy
758,380
+132,464
+21% +$5.52M ﹤0.01% 2291
2024
Q3 		$24.4M Buy
625,916
+84,894
+16% +$3.39M ﹤0.01% 2596
2024
Q2 		$18.5M Buy
541,022
+186,434
+53% +$4.89M ﹤0.01% 2750
2024
Q1 		$8.91M Buy
354,588
+109,897
+45% +$3.02M ﹤0.01% 3439
2023
Q4 		$7.22M Buy
244,691
+97,775
+67% +$2.96M ﹤0.01% 3624
2023
Q3 		$4.64M Buy
146,916
+42,437
+41% +$1.16M ﹤0.01% 3808
2023
Q2 		$2.7M Buy
104,479
+60,285
+136% +$1.6M ﹤0.01% 4223
2023
Q1 		$1.06M Sell
44,194
-33,633
-43% -$767K ﹤0.01% 4821
2022
Q4 		$1.52M Sell
77,827
-16,846
-18% -$333K ﹤0.01% 4635
2022
Q3 		$1.99M Sell
94,673
-40,992
-30% -$987K ﹤0.01% 4439
2022
Q2 		$2.64M Buy
135,665
+104,363
+333% +$2.46M ﹤0.01% 4319
2022
Q1 		$690K Buy
31,302
+1,364
+5% +$27.8K ﹤0.01% 5210
2021
Q4 		$477K Buy
29,938
+18,913
+172% +$294K ﹤0.01% 5583
2021
Q3 		$220K Sell
11,025
-34,091
-76% -$554K ﹤0.01% 5949
2021
Q2 		$781K Buy
45,116
+44,502
+7,248% +$798K ﹤0.01% 5227
2021
Q1 		$12K Sell
614
-89,387
-99% -$1.71M ﹤0.01% 6890
2020
Q4 		$1.57M Buy
90,001
+41,848
+87% +$823K ﹤0.01% 4356
2020
Q3 		$928K Sell
48,153
-53,868
-53% -$1.16M ﹤0.01% 4259
2020
Q2 		$1.99M Buy
102,021
+98,599
+2,881% +$1.65M ﹤0.01% 3609
2020
Q1 		$48K Sell
3,422
-2,810
-45% -$46.1K ﹤0.01% 5477
2019
Q4 		$152K Buy
6,232
+5,545
+807% +$59.1K ﹤0.01% 5512
2019
Q3 		$7K Buy
+687
New +$8.43K ﹤0.01% 6298

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's MIRM Position: Q2 2026 in Review

Morgan Stanley reduced its Mirum Pharmaceuticals (MIRM) stake by 33% in Q2 2026, selling an estimated $17.4M and leaving 351,404 shares worth $41.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

Morgan Stanley first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. The position peaked at $49.1M in Q3 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Morgan Stanley held 351,404 shares of Mirum Pharmaceuticals worth $41.1M as of Q2 2026.
  • Morgan Stanley sold 173,162 Mirum Pharmaceuticals shares in Q2 2026, an estimated $17.4M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2428 holding.
  • Morgan Stanley first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • Morgan Stanley's Mirum Pharmaceuticals position peaked at $49.1M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.